Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response

OBJECTIVES: To assess to what extent leflunomide (LEF) and hydroxychloroquine (HCQ) therapy in patients with primary Sjögren’s syndrome (RepurpSS-I) targets type I IFN-associated responses and to study the potential of several interferon associated RNA-based and protein-based biomarkers to predict a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamkour, Safae, van der Heijden, Eefje HM, Lopes, Ana P, Blokland, Sofie L M, Bekker, Cornelis P J, Van Helden-Meeuwsen, Cornelia G, Versnel, Marjan A, Kruize, Aike A, Radstake, Timothy RDJ, Leavis, Helen L, Hillen, Maarten R, van Roon, Joel AG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Sjögren Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401261/
https://www.ncbi.nlm.nih.gov/pubmed/37532471
http://dx.doi.org/10.1136/rmdopen-2023-002979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401261/
https://www.ncbi.nlm.nih.gov/pubmed/37532471
http://dx.doi.org/10.1136/rmdopen-2023-002979

Ejemplares similares